- Companies
- Equashield
Equashield Valuation, Funding & Investors
Equashield is valued at $1.3B as of October 2022.
Last Equashield valuation
$1.3B
Secondary · Oct 2022
Key investors in Equashield
Nordic Capital
About Equashield
Equashield is a medical device manufacturer specializing in closed system transfer devices that prevent exposure to hazardous drugs during compounding and administration. Its flagship product, the Equashield PRO platform, features a needle-free, mechanically closed system compliant with USP <800> standards for handling antineoplastic agents. Headquartered in Port Washington, New York, with operations originating from Israel since its founding in 2007, the company supplies over 1,000 hospitals across North America, Europe, and Asia. Equashield holds FDA 510(k) clearance and NIOSH certification, and it partners with major distributors like McKesson and Cardinal Health to protect pharmacists and nurses from aerosols and vapors.
Founded
2004
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$1.3B (Oct 2022)
Sectors
Equashield Valuation
Equashield is currently valued at $1.3B, based on its secondary sale in October 2022.
The $300M round was led by Nordic Capital.
Equashield valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Oct 2022 | Secondary | $1.3B |
Equashield Funding History
Equashield has 1 recorded secondary share sale and no primary funding rounds.
Equashield funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Oct 2022 | Secondary | Nordic Capital (lead) | $300M | $1.3B | Equashield is an Israeli medical device company founded in 2008 that develops and manufactures closed-system transfer devices (CSTDs) and other compounding technologies designed to protect healthcare professionals from exposure to hazardous drugs during drug preparation and administration. The company operates a highly automated manufacturing facility in Tefen, Israel, with approximately 460 employees and has achieved profitability without requiring significant external capital investment beyond initial founder contributions. On October 6, 2022, Nordic Capital, a leading Nordic private equity firm with €27 billion in assets under management, acquired a 25% stake in Equashield for $300 million, valuing the company at $1.3 billion. This represented the first Nordic Capital investment in an Israeli company. The transaction was structured as an acquisition of existing shareholdings from founders and early investors, including CEO and co-founder Eric Shem-Tov, rather than new capital injection into the company. Prior to the deal, the company distributed approximately $28 million in dividends to shareholders. Equashield has generated sales in the hundreds of millions of dollars annually to hospitals globally, with the company reporting revenues of €120 million in 2024. The company's strong profitability stems from its highly automated manufacturing process, which incorporates artificial intelligence in production and requires significantly fewer employees than comparable competitors. At the time of the Nordic Capital investment, Equashield was developing a novel automated drug compounding system and planning to establish an additional production facility to support continued growth. |
Who has invested in Equashield?
1 investor has backed Equashield across its funding rounds, including Nordic Capital.
Lead investors include Nordic Capital.
Equashield Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
This data is available for Pro users. Sign up to see all 1 Equashield investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialEquashield Competitors
Equashield competitors include listed companies like Arcs Co, VCANBIO and Weigao Group, and private ones like EverlyWell, Wilson Wolf Corporation and Rapid Medical.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $100M | - | $1.3B | 13.0x | ||
| Publicly listed | $4B | $185M | $1.3B | 0.2x | ||
| Private | - | $55M | $1.3B | - | ||
| Publicly listed | $217M | $44M | $1.3B | 4.3x | ||
| Publicly listed | $227M | $56M | $1.3B | 4.7x | ||
| Private | - | - | $1.3B | - |
Equashield Public Comps
Equashield is still privately-owned, but its public comps include Arcs Co, Sinocare, Medartis, Vitrolife, VCANBIO, Weigao Group, Sansure Biotech, ChemoMetec, Conmed and Tandem Diabetes Care.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $4B | $185M | 0.2x | 0.2x | 4.8x | 4.9x | |||
| $695M | $43M | 1.9x | 1.8x | 31.0x | 15.3x | |||
| $328M | $54M | 4.7x | 4.0x | 28.4x | 22.3x | |||
| $351M | ($449M) | 3.8x | 3.7x | (3.0x) | 11.9x | |||
| $217M | $44M | 4.6x | 4.3x | 22.8x | 25.1x | |||
| $227M | $56M | 4.6x | 4.7x | 18.6x | 13.4x | |||
| $245M | $48M | 4.2x | 4.1x | 21.3x | 14.6x | |||
| $79M | $44M | 16.3x | 15.8x | 29.2x | 29.8x | |||
This data is available for Pro users. Sign up to see all Equashield competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Equashield
| When was Equashield founded? | Equashield was founded in 2004. |
| Where is Equashield headquartered? | Equashield is headquartered in New York City, NY, United States. |
| Is Equashield publicly listed? | No, Equashield is a private, VC-backed company. |
| What is Equashield's valuation? | Equashield was last valued at $1.3B in its secondary sale in October 2022. |
| Who are Equashield's investors? | Equashield's investors include Nordic Capital. |
| Which companies are comparable to Equashield? | Companies comparable to Equashield include EverlyWell, Arcs Co, Wilson Wolf Corporation, VCANBIO, Weigao Group and Rapid Medical. |
See companies similar to Equashield
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




